Oncoinvent presents corporate update in live webcast
Oslo, Norway, 29 April 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is hosting a live webcast at 8:00 AM CET today, Wednesday, 29 April 2026.
· Presenters: CEO Øystein Soug, CFO Ramzi Amri · Time: 8:00am CET · Webcast link: https://qcnl.tv/p/ZTQdC_4834AF6CKrux8XCw
Highlights:
· Recruited and randomized 37 patients (accumulated, ITT*) into the ovarian Phase 2 trial · Secured new patent expanding protection for Radspherin[®] · Published positive final data from Phase 1 trial of Radspherin[®] to treat ovarian cancer · Journal: Gynecologic Oncology · Conference: ESGO European Gynaecological Oncology Congress 2026
· Appointed Dr Ramzi Amri as CFO
The presentation material and the recording of the webcast will be made available at www.oncoinvent.com.
Oncoinvent reports its financial results on a half-yearly basis, complemented by quarterly business updates to keep stakeholders informed and ensure ongoing transparency.
For further information, please contact:
Oystein Soug, Chief Executive Officer Email: IR@oncoinvent.com
About Oncoinvent
Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent's product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).